What is keytruda's fda approval date for its wide application?

Pembrolizumab (Keytruda) received its FDA approval for broad (widespread) use—based on its first FDA approval, which covered multiple solid-tumor indications—on September 4, 2014.

If you tell me which “wide application” you mean (e.g., melanoma, non–small cell lung cancer, any MSI-H/dMMR tumor, or adjuvant settings), I can give the exact FDA approval date for that specific broadening indication.